Post-Marketing Pharmacovigilance: How a Safety Alert Travels from the Patient to the Laboratory

Experience gained through everyday use expands what is known about a medicine. People of different ages, patients taking several treatments at the same time, and varied clinical conditions can reveal information that does not always emerge in studies conducted before authorization.

Pharmacovigilance organizes this information to detect, assess, understand, and prevent possible adverse effects or other medicine-related problems. Its value depends on a communication chain involving patients, healthcare professionals, facilities, distributors, marketing authorization holders, and health authorities.

When the process works, a report becomes useful information. Each participant contributes data, maintains records, and sends the case to the appropriate responsible party. Specialists then analyze whether the observation matches other reports or indicates a potential risk that deserves closer study.

A Report Begins with an Observation

A possible adverse reaction may be noticed by the patient, a family member, a physician, a pharmacist, or nursing staff. It may also be reported through a healthcare facility, a customer service line, a sales representative, or a channel established by the health authority.

At this stage, the goal is to capture basic information: who experienced the event, which product was used, what happened, and when it occurred. The dose, indication, other medicines administered, and lot information are also useful when available. The report does not need to prove on its own that the medicine caused the event; it communicates a suspicion that must be documented and evaluated.

In Guatemala, the DRCPFA provides pharmacovigilance forms and services for submitting reports. This institutional channel allows patients and professionals to contribute information to health surveillance and enables authorities to incorporate it into their review processes.

From Initial Notice to a Documented Case

After receiving a report, the pharmacovigilance team verifies that it contains the minimum information needed to understand what happened and requests additional details when necessary. It then arranges the events chronologically, protects the patient’s identity, and sends the case to the people who must review it within the applicable deadlines.

Validating the report does not mean concluding that the medicine caused the event. It means confirming that there is enough information to study it. To determine whether a relationship may exist, specialists review the patient’s history, other treatments, known product information, and whether similar cases have occurred.

A quality complaint may also follow a parallel path. A change in appearance, damaged packaging, or a possible temperature deviation must reach the quality department, which will review the lot, storage conditions, and distribution history. If the case also involves an adverse event, quality and pharmacovigilance teams need to coordinate.

Information Moves Among Several Responsible Parties

The distributor may be one of the first points of contact, but it does not act alone. It must send the report to the laboratory or marketing authorization holder—the company responsible for the medicine before the health authority. It also preserves evidence of the communication and helps obtain additional information when requested. The authorization holder compiles the information received and fulfills its obligations to the authority.

Authorities review domestic and international reports, publish bulletins or alerts, and may request additional measures. These can include changes to product information, communications to professionals, enhanced monitoring, or, in specific situations, lot recalls. The European Medicines Agency describes this work as a continuous process of detecting, assessing, preventing, and communicating risks.

Timely communication also protects availability. A wAgencias J.I. Cohen Connects the Report to Operations

Agencias J.I. Cohen has a pharmacovigilance unit authorized by the DRCPFA, according to corporate information provided by the company. Its structure also includes regulatory affairs, quality assurance, inventory, distribution, and service for different private-sector channels.

This combination helps turn a report into concrete action. Depending on the case, the team may need to contact the laboratory, locate units from a specific lot, review how the product was stored, or contact the customer who received it. Coordination across departments makes it possible to reconstruct the journey without losing important information.

Pharmacovigilance strengthens trust when it turns observations from real-world use into responsible action. For patients and professionals, reporting contributes knowledge. For laboratories and distributors, listening, documenting, and communicating accurately makes it possible to support the medicine throughout its commercial life and sustain safety-focused distribution.

ell-defined response makes it possible to act on the product or lot involved without extending the measure beyond what is necessary. To achieve this, inventory and distribution records must show where each unit is located.